Mint Venture Partners

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.

Medinno Inc. is a biotechnology company founded in 2016 and located in Suwon, South Korea. The company focuses on research and development of cell therapeutics derived from neural stem cells sourced from adult brain tissue. Medinno aims to address degenerative neurological diseases, including stroke and Alzheimer's disease, as well as conditions such as hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, and severe intraventricular hemorrhages. By utilizing advanced technology, Medinno seeks to provide effective treatment options for these serious medical conditions, particularly in vulnerable populations like premature infants.

Aimedbio is a healthcare company focused on developing therapeutic solutions for patients suffering from serious brain diseases. The company specializes in creating therapeutic systems and medicines aimed at treating neuro-oncological and degenerative conditions. By addressing the needs of patients with refractory brain diseases, including cancer, Aimedbio strives to enhance their quality of life through innovative treatment options.

Humanscape, Inc. is a health-tech company based in Seoul, South Korea, that focuses on improving the treatment options for patients with rare and intractable diseases. Founded in 2016, the company utilizes blockchain technology to create a platform that collects and processes comprehensive health data, including genotype, clinical, and phenotype information. By systematically compiling this data into a ready-to-use dataset, Humanscape enables pharmaceuticals and researchers to streamline the drug development process, ultimately reducing both the time and cost associated with bringing new treatments to market. The platform aims to enhance collaboration among medical practitioners and researchers, facilitating advancements in the understanding and treatment of various incurable diseases.

SanaHeal is a company focused on developing innovative bioadhesive biomaterials, including tapes, pastes, and powders, designed to bind tissues or organs. Its bioadhesive tapes serve as an alternative to traditional sutures, promoting healing while reducing complications following surgery. This technology aims to transform the treatment of wounds and bleeding, enhancing patient outcomes. Additionally, SanaHeal's platform offers mechanical integration solutions that assist in the care of patients with multiple traumatic injuries, ensuring they receive the necessary intensive care.

Activ Surgical Inc. is a digital surgery company based in Boston, Massachusetts, focused on enhancing surgical efficiency, accuracy, and patient outcomes through advanced technology. Founded in 2014, the company has developed a robotic surgery platform that integrates computer vision, artificial intelligence, and robotics to assist surgeons during complex procedures. One of its key products is the Smart Tissue Autonomous Robot (STAR), which aims to revolutionize surgical practices by improving intraoperative decision-making and reducing the risk of unintended surgical complications. The platform is scalable and patent-protected, designed to support surgeons with augmented reality and data-driven insights, ultimately making surgeries safer and more effective.

BeauBrain Healthcare focuses on transforming the approach to Alzheimer’s Disease and dementia by shifting from post-diagnosis treatment to pre-emptive intervention. With over 55 million people affected by dementia globally, the company's diagnostic platform offers a suite of cognitive tests and brain imaging scans that help predict the risk of developing these neurodegenerative diseases. By analyzing brain activity and structure, BeauBrain's solutions can identify subtle changes years before symptoms manifest, allowing for proactive measures to delay or prevent cognitive decline. Their personalized cognitive training platform, along with predictive analysis of specific biomarkers, aims to pave the way for precision medicine in Alzheimer’s treatment. BeauBrain Healthcare is committed to addressing the growing medical and social burdens associated with dementia through early identification and intervention strategies.

Seawith is a biotechnology startup focused on producing cell-cultured steak derived from seaweed. The company has developed Yo.od, a low-iodine seaweed designed for consumers who have low iodine resistance and high iodine sensitivity. Seawith utilizes its own culture media made from microalgae, which not only enhances the nutritional profile but is also more cost-effective due to the plentiful availability of microalgae. By creating clean meat in a laboratory setting, Seawith aims to eliminate the need for raising and slaughtering livestock, delivering a product that mimics traditional meat in taste and texture while being both delicious and affordable.

Organoid Sciences is a drug development company based in Seongnam-si, South Korea, founded in 2018. The company specializes in organoid-based treatments and utilizes cannabinoid-based technology to create drugs aimed at addressing various incurable diseases. In addition to drug development, Organoid Sciences provides drug screening services and focuses on regenerative medicine, contributing to advancements in healthcare solutions.

Sonic Incytes Medical Corp is a medical device company based in Vancouver, Canada, focused on developing handheld ultrasound solutions for the assessment and monitoring of chronic liver diseases. Incorporated in 2012, the company aims to enhance routine liver health evaluation through non-invasive methods that provide reliable diagnostic accuracy. Its portable ultrasound devices are designed for point-of-care diagnostics and procedure guidance, enabling healthcare practitioners to improve the standard of care in quantifying conditions such as fatty liver disease. Through its innovative technology, Sonic Incytes seeks to facilitate better management of liver health for patients.

Key Proteo is a company focused on developing advanced peptide screening methods for newborns, aiming to enhance existing newborn screening programs. By employing multiplex analysis techniques for extremely low-abundance proteins from just a few drops of blood, Key Proteo enables early identification of genetic diseases before they become clinically apparent. This innovative approach utilizes surrogate peptide markers analyzed through mass spectrometry, allowing healthcare providers to target both new and existing genetic conditions effectively. The company's technology seeks to alter the clinical trajectory of these diseases, ultimately improving the quality of life for affected infants and facilitating timely medical intervention.

GenoTwin focuses on integrating genomics into public health to tackle infectious disease challenges. The company has developed an innovative genomics platform that leverages advanced genomics, artificial intelligence, and computational biology. This platform serves clinicians, public health officials, and researchers by enhancing capabilities in four main areas: pathogen detection, pathogen surveillance, immune and resistance assessment, and precision treatment. Additionally, GenoTwin's technology facilitates the epidemiologic analysis of infectious diseases and supports precision medicine, enabling healthcare providers to address emerging pathogens early. This approach aims to reduce mortality, improve treatment effectiveness, and enhance overall public health outcomes.

Charco Neurotech is a medical technology company focused on developing non-invasive wearable devices aimed at improving the quality of life for individuals with Parkinson's disease. The company's primary product is designed to modulate sensory dysfunction, which assists users in enhancing their movement speed. By providing a solution that allows people with Parkinson's to maintain a more normal lifestyle, Charco Neurotech addresses significant challenges faced by this population, ultimately contributing to better overall health and well-being.

Activ Surgical Inc. is a digital surgery company based in Boston, Massachusetts, focused on enhancing surgical efficiency, accuracy, and patient outcomes through advanced technology. Founded in 2014, the company has developed a robotic surgery platform that integrates computer vision, artificial intelligence, and robotics to assist surgeons during complex procedures. One of its key products is the Smart Tissue Autonomous Robot (STAR), which aims to revolutionize surgical practices by improving intraoperative decision-making and reducing the risk of unintended surgical complications. The platform is scalable and patent-protected, designed to support surgeons with augmented reality and data-driven insights, ultimately making surgeries safer and more effective.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Mezoo is a medical device manufacturing company focused on developing biomedical sensor technology aimed at enhancing human health through accurate diagnoses. The company has created a compact, patch-type electrocardiogram that can be affixed to a patient’s chest. This device monitors heart activity in real-time, allowing physicians to effectively manage and prevent heart disease. By providing essential health data, Mezoo's technology supports healthcare professionals in delivering timely and informed medical care.

NEXTON is a South Korean indoor vertical farming company based in Seoul, founded in 2017. It specializes in the cultivation of agricultural products and food sales, utilizing hydroponic methods to grow a variety of crops, including leafy greens, Korean strawberries, and pharmaceutical plants, without the use of pesticides or herbicides. The farm operates under optimal conditions, maintaining temperatures between 10-20°C year-round without the need for active heating or cooling systems. NEXTON employs photosynthetically-active LED lighting and a fully-recycled nutrient water system to ensure sustainable and chemical-free production. In addition to vegetables and herbs, the company also explores the cultivation of plants for cosmetic use.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.